Deworming drug could tame ulcerative colitis, small trial hopes
NCT ID NCT06335160
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding mebendazole, a common deworming medication, to standard mesalamine therapy can improve symptoms in people with mild-to-moderate ulcerative colitis. 46 adults will take mebendazole or a placebo twice daily for 6 months. Researchers will measure changes in disease activity and blood markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mebendazole (a deworming medication)
- What this could lead to
- If it works, this could point toward a new, affordable add-on treatment for ulcerative colitis.
- What could go wrong
- This is a small, early-phase trial with only 46 people. Mebendazole is not a standard colitis drug, so it may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta Unuversity
RECRUITINGTanta, 34518, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a glass of pomegranate juice tame gut inflammation?